Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3461352rdf:typepubmed:Citationlld:pubmed
pubmed-article:3461352lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:3461352lifeskim:mentionsumls-concept:C0008533lld:lifeskim
pubmed-article:3461352lifeskim:mentionsumls-concept:C0018837lld:lifeskim
pubmed-article:3461352lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:3461352lifeskim:mentionsumls-concept:C1522326lld:lifeskim
pubmed-article:3461352lifeskim:mentionsumls-concept:C0027978lld:lifeskim
pubmed-article:3461352lifeskim:mentionsumls-concept:C0072434lld:lifeskim
pubmed-article:3461352lifeskim:mentionsumls-concept:C0139015lld:lifeskim
pubmed-article:3461352pubmed:issue803lld:pubmed
pubmed-article:3461352pubmed:dateCreated1986-9-17lld:pubmed
pubmed-article:3461352pubmed:abstractTextFactor IX concentrates, prepared by standard chromatographic techniques, are used primarily to treat patients with congenital factor IX deficiency. A local factor IX containing concentrate has now been prepared and heat treated. Following heat treatment, and reconstitution, the potency is 280 units per vial. The preparation, HNZFIX, has been compared with the currently available factor IX concentrate Prothrombinex. Following administration into patients with haemophilia B, ex vivo factor IX recovery and half life response have been compared for the two products. The mean recovery values were identical with an average 17 units per litre rise in factor IX activity obtained for each unit of factor IX concentrate administered per kg of body weight. For both products recovery measured as the K ratio was approximately 75% (0.75). The plasma half life responses were 17 and 22.2 h for the HNZFIX and PTX respectively. No unexpected side effects occurred with the HNXFIX which met all the British Pharmacopeia requirements for a therapeutic concentrate.lld:pubmed
pubmed-article:3461352pubmed:languageenglld:pubmed
pubmed-article:3461352pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3461352pubmed:citationSubsetIMlld:pubmed
pubmed-article:3461352pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3461352pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3461352pubmed:statusMEDLINElld:pubmed
pubmed-article:3461352pubmed:monthJunlld:pubmed
pubmed-article:3461352pubmed:issn0028-8446lld:pubmed
pubmed-article:3461352pubmed:authorpubmed-author:BennyA GAGlld:pubmed
pubmed-article:3461352pubmed:authorpubmed-author:WoodfieldD...lld:pubmed
pubmed-article:3461352pubmed:authorpubmed-author:BerryE WEWlld:pubmed
pubmed-article:3461352pubmed:authorpubmed-author:OckelfordP...lld:pubmed
pubmed-article:3461352pubmed:authorpubmed-author:JohnsA SASlld:pubmed
pubmed-article:3461352pubmed:issnTypePrintlld:pubmed
pubmed-article:3461352pubmed:day11lld:pubmed
pubmed-article:3461352pubmed:volume99lld:pubmed
pubmed-article:3461352pubmed:ownerNLMlld:pubmed
pubmed-article:3461352pubmed:authorsCompleteYlld:pubmed
pubmed-article:3461352pubmed:pagination408-9lld:pubmed
pubmed-article:3461352pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:3461352pubmed:meshHeadingpubmed-meshheading:3461352-...lld:pubmed
pubmed-article:3461352pubmed:meshHeadingpubmed-meshheading:3461352-...lld:pubmed
pubmed-article:3461352pubmed:meshHeadingpubmed-meshheading:3461352-...lld:pubmed
pubmed-article:3461352pubmed:meshHeadingpubmed-meshheading:3461352-...lld:pubmed
pubmed-article:3461352pubmed:meshHeadingpubmed-meshheading:3461352-...lld:pubmed
pubmed-article:3461352pubmed:meshHeadingpubmed-meshheading:3461352-...lld:pubmed
pubmed-article:3461352pubmed:meshHeadingpubmed-meshheading:3461352-...lld:pubmed
pubmed-article:3461352pubmed:meshHeadingpubmed-meshheading:3461352-...lld:pubmed
pubmed-article:3461352pubmed:meshHeadingpubmed-meshheading:3461352-...lld:pubmed
pubmed-article:3461352pubmed:meshHeadingpubmed-meshheading:3461352-...lld:pubmed
pubmed-article:3461352pubmed:meshHeadingpubmed-meshheading:3461352-...lld:pubmed
pubmed-article:3461352pubmed:meshHeadingpubmed-meshheading:3461352-...lld:pubmed
pubmed-article:3461352pubmed:meshHeadingpubmed-meshheading:3461352-...lld:pubmed
pubmed-article:3461352pubmed:meshHeadingpubmed-meshheading:3461352-...lld:pubmed
pubmed-article:3461352pubmed:year1986lld:pubmed
pubmed-article:3461352pubmed:articleTitleHeat treated New Zealand factor IX concentrate: comparison with Prothrombinex in patients with haemophilia B.lld:pubmed
pubmed-article:3461352pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3461352pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:3461352pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed